IRTCA Antibody AITR Binding Converts T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively addressing the growing global burden of cancer, with existing therapies often resulting in reduced quality of life for patients and significant medical expenses, highlighting the need for improved treatment methods that can enhance immune responses against cancer cells.
Innovation Solution
Development of IFN-γ-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragments that specifically bind to the human activation-inducible TNFR family receptor (AITR), converting regulatory T cells into TH1-like cells to enhance immune responses and increase the secretion of IFN-γ while decreasing TGF-β secretion, thereby targeting and reducing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then cancer cells are targeted, but patient quality of life is reduced and medical expenses increase
Solution Approach 1:
The invention changes the functional state of regulatory T cells by inducing conversion to TH1-like cells through AITR receptor stimulation, transforming their cytokine profile (increasing IFN-γ, decreasing TGF-β) to achieve anti-tumor effects while potentially reducing treatment toxicity
Solution Approach 2:
The invention converts regulatory T cells, which normally suppress immune responses and protect tumors, into beneficial TH1-like effector cells that actively attack cancer, transforming a harmful immune component into a therapeutic asset
2Productivity
If existing cancer therapies are administered, then tumor growth is targeted, but treatment outcomes are insufficient and toxicity increases
Solution Approach 1:
The invention harnesses the patient's own immune system, specifically converting endogenous regulatory T cells into anti-tumor TH1 cells, eliminating the need for external toxic chemotherapy agents and enabling the body to fight cancer with its own resources
Solution Approach 2:
The invention creates a dynamic immune response by inducing plasticity in regulatory T cells, allowing them to switch from a suppressive phenotype to an effector phenotype in response to AITR stimulation, providing adaptability in the anti-tumor immune response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IRTCA antibodies effectively convert regulatory T cells into TH1-like cells, boosting the immune response against cancer, potentially leading to reduced tumor growth and improved treatment outcomes with lower toxicity and extended therapeutic benefits.
Implementation Method 1
antibodies and fragments thereof that bind to a human activation-inducible TNFR family receptor (AITR) polypeptide
Data Source
AI summary
Provided are IFN-γ-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.